Endoscopic ultrasound-guided radiofrequency ablation for large branch-duct intraductal papillary mucinous neoplasms: Safety and efficacy trial

Abstract

Background and study aims

Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a nonsurgical treatment option for managing pancreatic lesions. We sought to evaluate the safety and efficacy of EUS-RFA for large (≥4 cm) branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs).

Patients and methods

Patients with a definitive diagnosis of BD-IPMN who declined or were unfit for surgery underwent EUS-RFA in a single-arm prospective trial. Ablation was performed using a 19G EUS-RFA needle. RFA applications were delivered up to a maximum threshold of 45 seconds or 400 ohms impedance. Safety was assessed using AGREE guidelines. Potential for efficacy was assessed using cyst volume and cyst fluid KRAS GNAS mutations using next-generation sequencing (NGS). Adverse events (AEs) were analyzed per RFA session, while response was analyzed per BD-IPMN.

Results

Thirty BD-IPMNs (mean diameter 4.6 ± 1.7 cm; 80% multilocular) in 25 participants (mean age 74.1 ± 8.3 years) underwent 41 EUS-RFA sessions. AEs occurred in 12.2% of procedures (5/41), the majority being AGREE Grade 3A (9.8%, 4/41).

During a mean follow-up of 18 ± 5 months, 22 of 28 BD-IPMNs (78.6%) achieved ≥ 50% reduction in cyst volume, and 11 (39.3%) demonstrated complete (≥90%) response. Among 26 BD-IPMNs that revealed KRAS GNAS mutations, follow-up NGS was performed in 17, with 88.2% showing loss of detectable mutations.

Conclusions

EUS-RFA in large, predominantly multilocular BD-IPMNs shows promising volumetric efficacy. Safety may be improved through refined energy delivery and technical advances. Molecular response remains exploratory and requires further validation. Long-term studies assessing progression-free outcomes are needed to define its role as an organ-preserving therapeutic option.

Keywords

Endoscopic ultrasonography - Pancreas - Intervention EUS - Endoscopy Upper GI Tract - RFA and ablative methods

Publication History

Received: 04 September 2025

Accepted after revision: 23 December 2025

Accepted Manuscript online:
24 December 2025

Article published online:
21 January 2026

• References

• 1 Ohtsuka T, Fernandez-del Castillo C, Furukawa T. et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology 2024; 24: 255-270
• 2 Ohno E, Balduzzi A, Hijioka S. et al. Association of high-risk stigmata and worrisome features with advanced neoplasia in intraductal papillary mucinous neoplasms (IPMN): A systematic review. Pancreatology 2024; 24: 48-61
• 3 Scheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 2015; 148: 824-848.e822
• 4 Sharib J, Esserman L, Koay EJ. et al. Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective. Surgery 2020; 168: 601-609
• 5 Teoh AY, Seo DW, Brugge W. et al. Position statement on EUS-guided ablation of pancreatic cystic neoplasms from an international expert panel. Endosc Int Open 2019; 7: E1064-e1077
• 6 Cho SH, Seo D-W, Oh D. et al. Long-term outcomes of endoscopic ultrasound-guided ablation vs surgery for pancreatic cystic tumors. Clin Gastroenterol Hepatol 2024; 22: 1628-1636.e4
• 7 Barthet M, Giovannini M, Gasmi M. et al. Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasms. Endosc Int Open 2021; 9: E1178-E1185
• 8 Pai M, Habib N, Senturk H. et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg 2015; 7: 52
• 9 Younis F, Ben-Ami Shor D, Lubezky N. et al. Endoscopic ultrasound-guided radiofrequency ablation of premalignant pancreatic-cystic neoplasms and neuroendocrine tumors: prospective study. Europ J Gastroenterol Hepatol 2022; 34: 1111-1115
• 10 Ren R, Krishna SG, Chen W. et al. Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation. Modern Pathology 2021; 34: 438-444
• 11 Krishna SG, Hart PA, Malli A. et al. Endoscopic ultrasound-guided confocal laser endomicroscopy increases accuracy of differentiation of pancreatic cystic lesions. Clin Gastroenterol Hepatol 2020; 18: 432-440 e436
• 12 Church S, Rogers E, Rockwood K. et al. A scoping review of the Clinical Frailty Scale. BMC Geriatrics 2020; 20: 1-18
• 13 Charlson ME, Carrozzino D, Guidi J. et al. Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom 2022; 91: 8-35
• 14 Radadiya D, Brahmbhatt B, Reddy C. et al. Efficacy of combining aggressive hydration with rectal indomethacin in preventing post-ERCP pancreatitis: a systematic review and network meta-analysis. J Clin Gastroenterol 2022; 56: e239-e249
• 15 Nass KJ, Zwager LW, van der Vlugt M. et al. A novel classification for adverse events in gastrointestinal endoscopy: the AGREE classification. Gastrointest Endosc 2022; 95: 1078-1085.e8
• 16 Banks PA, Bollen TL, Dervenis C. et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102-111
• 17 Ryoo DY, Koehler B, Rath J. et al. A comparison of single dimension and volume measurements in the risk stratification of pancreatic cystic lesions. J Clin Med 2023; 12: 5871
• 18 Papaefthymiou A, Johnson GJ, Maida M. et al. Performance and safety of EUS ablation techniques for pancreatic cystic lesions: A systematic review and meta-analysis. Cancers (Basel) 2023; 15
• 19 Zhou Y, Tao L, Qiu J. et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduc Targeted Ther 2024; 9: 132
• 20 Coluccio C, Cappetta S, Romagnoli G. et al. Endoscopic-ultrasound-guided radiofrequency ablation for pancreatic tumors. J Clin Med 2025; 14: 495
• 21 Abdelbaki A, Hawa F, Krishna SG. An unexpected adverse event of radiofrequency ablation for intraductal papillary mucinous neoplasm. Gastroenterology 2025; 169: e8-e11
• 22 DeWitt JM, Al-Haddad M, Sherman S. et al. Alterations in cyst fluid genetics following endoscopic ultrasound-guided pancreatic cyst ablation with ethanol and paclitaxel. Endoscopy 2014; 46: 457-464
• 23 Krishna SG, Ardeshna DR, Shah ZK. et al. Intracystic injection of large surface area microparticle paclitaxel for chemoablation of intraductal papillary mucinous neoplasms: Insights from an expanded access protocol. Pancreatology 2024; 24: 289-297